Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2-carbamimidoylbenzo[b]thiophen-4-yloxy)phenylacetic acid methyl ester
-
-
(2-carbamimidoylbenzo[b]thiophen-6-yloxy)thiophen-2-ylacetic acid ethyl ester
-
-
(2E)-3-[(7S)-7-[2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamido]-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]prop-2-enoic acid
-
-
(2R)-N-1,3-benzothiazol-5-yl-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanamide
-
-
(2R)-N-[4-(1H-benzimidazol-1-yl)-2-fluorophenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanamide
-
-
(2S)-N-1,3-benzothiazol-5-yl-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanamide
-
-
(2S)-N-[4-(1H-benzimidazol-1-yl)-2-fluorophenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanamide
-
-
(7S)-2-methyl-7-phenyl-7-[4-(4H-1,2,4-triazol-4-yl)benzamido]-6,7,8,9-tetrahydropyrido[1,2-a]indole-10-carboxylic acid
-
-
(7S)-2-methyl-7-phenyl-7-[[5-(4H-1,2,4-triazol-4-yl)pyridine-2-carbonyl]amino]-6,7,8,9-tetrahydropyrido[1,2-a]indole-10-carboxylic acid
-
-
(7S)-7-[2-chloro-4-(1H-tetrazol-1-yl)benzamido]-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indole-10-carboxylic acid
-
-
(7S)-7-[2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamido]-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indole-10-carboxylic acid
-
-
(7S)-7-[2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamido]-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indole-10-carboxamide
-
-
1,5-dansyl-Glu-Gly-Arg chloromethylketone
-
1-(3-chloro-4-[[(2R)-2,8-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]carbamoyl]phenyl)-1H-benzimidazole-5-carboxylic acid
-
-
2,6-dichloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)-N-[(2R)-8-methyl-2-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]benzamide
-
-
2,6-dichloro-N-((R)-2-((S)-1-hydroxyethyl)-8-methyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
-
2,6-dichloro-N-[(2R)-10-hydroxy-2,7-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
-
2,6-dichloro-N-[(2R)-2,8-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
-
2,6-dichloro-N-[(2R)-2-(3,4-difluorophenyl)-8-methyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
-
2,6-dichloro-N-[(2R)-2-(3-fluorophenyl)-8-methyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
-
2,6-dichloro-N-[(2R)-2-(4-fluorophenyl)-8-methyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
-
2,6-dichloro-N-[(2R)-8-methyl-2-(3-methylphenyl)-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
-
2,6-dichloro-N-[(2R)-8-methyl-2-[1-(propan-2-yl)-1H-1,2,3-triazol-4-yl]-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
-
2,6-dichloro-N-[(3R)-3,7-dimethyl-2,3,4,9-tetrahydro-1H-carbazol-3-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
-
2-(2-carbamimidoylbenzo[b]thiophen-4-yloxy)propionic acid methyl ester
-
-
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenyl-N-(4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl)propanamide
-
-
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenyl-N-[4-(4-phenyl-1H-imidazol-1-yl)phenyl]propanamide
-
-
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-N-(4-cyanophenyl)-3-phenylpropanamide
-
-
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-N-(4-methylphenyl)-3-phenylpropanamide
-
-
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-N-(4-phenoxyphenyl)-3-phenylpropanamide
-
-
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-N-(4-[(6-chloropyridazin-3-yl)sulfamoyl]phenyl)-3-phenylpropanamide
-
-
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-N-(5-fluoro-2-methylphenyl)-3-phenylpropanamide
-
-
2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenyl-N-(2'-sulfamoylbiphenyl-4-yl)propanamide
-
-
2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenyl-N-[4-(5-phenyl-1H-imidazol-4-yl)phenyl]propanamide
-
-
2-(5-carbamimidoyl-1H-indol-3-yl)-N-(2'-sulfamoylbiphenyl-4-yl)acetamide
-
-
2-(5-carbamimidoyl-1H-indol-3-yl)-N-(4-ethylphenyl)-3-phenylpropanamide - 1H-benzimidazole
-
(1:1)
2-(7-carbamimidoylnaphthalen-1-yl)-N-[2-(1-ethoxyethenyl)cyclohexyl]-3-phenylpropanamide
-
-
2-([2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)-N-ethylcyclohexanecarboxamide
-
-
2-([2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxylic acid
-
-
2-amidino-4-iodobenzothiophene
-
-
2-chloro-N-[(2R)-2-(3-methoxyphenyl)-8-methyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
-
2-chloro-N-[(2R)-8-methyl-2-phenyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
-
2-chloro-N-[(7S)-10-cyclopropyl-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
-
2-chloro-N-[(7S)-10-[(E)-(hydroxyimino)methyl]-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
-
2-chloro-N-[(7S)-2-methyl-7-phenyl-10-(2,2,2-trifluoro-1-hydroxyethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
-
2-chloro-N-[(7S)-2-methyl-7-phenyl-10-(2H-tetrazol-5-yl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
-
2-chloro-N-[3-methyl-1-(4-methyl-2-nitrophenyl)pyrrolidin-3-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenyl-N-[4-(pyrrolidin-1-ylcarbonyl)phenyl]acetamide
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (1,3-dimethyl-1H-pyrazol-5-yl)carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (2,4-difluorophenyl)carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (2,6-difluorophenyl)carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (2-fluorophenyl)carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (2-methylphenyl)carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (2-[[(2-methylpropyl)amino]methyl]phenyl)carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (3,5-dimethyl-1,2-oxazol-4-yl)carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (3,5-dimethyl-1H-pyrazol-4-yl)carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (3-fluorophenyl)carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (4-fluorophenyl)carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (4-methoxyphenyl)carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl phenylcarbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [1,3-dimethyl-5-[(propan-2-ylamino)methyl]-1H-pyrazol-4-yl]carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [1-methyl-3-[(methylamino)methyl]-1H-pyrazol-5-yl]carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [2-(aminomethyl)phenyl]carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [2-(piperazin-1-ylmethyl)phenyl]carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [2-[(dimethylamino)methyl]phenyl]carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [2-[(methylamino)methyl]phenyl]carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [4-[(4-methylpiperazin-1-yl)methyl]phenyl]carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [4-[2-(dimethylamino)ethoxy]phenyl]carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [5-[(ethylamino)methyl]-1,3-dimethyl-1H-pyrazol-4-yl]carbamate
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-N,2-diphenylacetamide
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-N-(2-methoxyphenyl)-2-phenylacetamide
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-N-(3-methoxyphenyl)-2-phenylacetamide
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-N-(4-methoxyphenyl)-2-phenylacetamide
-
-
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-N-[2-(dimethylamino)ethyl]-2-phenylacetamide
-
-
2-[(2-carbamimidoyl-1-benzothiophen-6-yl)oxy]-2-(4-fluorophenyl)acetamide
-
-
2-[(2-carbamimidoyl-6-fluoro-1-benzothiophen-4-yl)oxy]-2-phenylethyl phenylcarbamate
-
-
2-[(2-carbamimidoyl-6-fluoro-1-benzothiophen-4-yl)oxy]-2-phenylethyl [2-(aminomethyl)phenyl]carbamate
-
-
2-[(2-carbamimidoyl-6-fluoro-1-benzothiophen-4-yl)oxy]-2-phenylethyl [2-[(dimethylamino)methyl]phenyl]carbamate
-
-
3-(1-[4-(1H-benzimidazol-1-yl)phenyl]-2-oxopyrrolidin-3-yl)-1-benzothiophene-5-carboximidamide
-
-
3-(2-carbamimidoylbenzo[b]thiophen-6-yloxy)-3-(4-chlorophenyl)propionic acid methyl ester
-
-
3-(2-[4-(1H-benzimidazol-1-yl)phenyl]-1-benzyl-2-oxoethyl)-1-benzothiophene-5-carboximidamide
-
-
3-(4-aminophenyl)-N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1-benzothiophen-3-yl)propanamide
-
-
3-(4-aminophenyl)-N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)propanamide
-
-
3-[(7R)-7-[2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamido]-2-methyl-7-phenyl-4a,6,7,8,9,10a-hexahydropyrido[1,2-a]indol-10-yl]propanoic acid
-
-
3-[3-([4-(1H-benzimidazol-1-yl)phenyl]amino)-2-(5-carbamimidoyl-1H-indol-3-yl)-3-oxopropyl]benzoic acid
-
-
4-(([2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanoyl]amino)methyl)-N-[5-(methylsulfonyl)-1H-benzimidazol-2-yl]benzamide
-
-
4-(2-carbamimidoylbenzo[b]thiophen-6-yloxy)-4-(4-chlorophenyl) butyric acid methyl ester
-
-
4-(benzyloxy)-1-benzothiophene-2-carboximidamide
-
-
4-([[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy](phenyl)acetyl]amino)-N,N-dimethylbenzamide
-
-
4-cyano-2-fluoro-N-(10-hydroxy-2,7-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl)benzamide
-
-
4-phenyl-1-benzothiophene-2-sulfinimidamide
-
-
4-[phenyl(3-phenyl[1,2,4]oxadiazol-5-yl)methoxy]benzo[b]thiophene-2-carboxamidine
-
-
5-(3,4-dimethoxyphenyl)benzo[b]thiophene-2-carboxamidine
-
-
5-(benzyloxy)-1-benzothiophene-2-carboximidamide
-
-
5-phenyl-1-benzothiophene-2-carboximidamide
-
-
6-(2-phenylethoxy)-1-benzothiophene-2-carboximidamide
-
-
6-(3,4-dimethoxyphenyl)-1-benzothiophene-2-carboximidamide
-
-
6-(3-chloro-4-fluorobenzyloxy)benzo[b]thiophene-2-carboxamidine
-
-
6-(pyridin-3-ylmethoxy)-1-benzothiophene-2-carboximidamide
-
-
6-(thiophen-2-ylmethoxy)benzo[b]thiophene-2-carboxamidine
-
-
6-benzyloxybenzo[b]thiophene-2-carboxamidine
-
-
6-[(2-chlorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
-
6-[(2-fluorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
-
6-[(2-methoxybenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
-
6-[(3,4-difluorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
-
6-[(3-chlorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
-
6-[(3-fluorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
-
6-[(3-methoxybenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
-
6-[(4-chloro-3-fluorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
-
6-[(4-chlorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
-
6-[(4-fluorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
-
6-[(4-methoxybenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
-
6-[(4-methylbenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
-
6-[1-(4-fluorophenyl)ethoxy]-1-benzothiophene-2-carboximidamide
-
-
aptamer
-
RNA aptamers isolated by iterative in vitro selection technique, complete inhibition at 0.00004 mM, inhibition is reversed by specific antidotes, i.e. oligonucleotides, complementary to the aptamers
-
Bovine pancreatic trypsin inhibitor
-
-
-
BPTI
Kunitz-type inhibitor, competitive, reversible inhibition, low molecular weight heparin binding to fIXa enhances reactivity of fIXa with the Kunitz-type inhibitor BPTI
-
D-Phe-Pro-Arg chloromethylketone
-
enoxaparin
competitive, reversible inhibition
ethyl 1-[4-([[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy](phenyl)acetyl]amino)phenyl]-1H-imidazole-2-carboxylate
-
-
ethyl 2-([2-(5-carbamimidoyl-1,1-dioxido-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxylate
-
-
ethyl 2-([2-(5-carbamimidoyl-1-benzofuran-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxylate
-
-
ethyl 2-([2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxylate
-
-
ethyl [(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]acetate
-
-
ethyl [(2-carbamimidoyl-1-benzothiophen-6-yl)oxy]acetate
-
-
ethyl [4-[([2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethoxy]carbonyl)amino]-3,5-dimethyl-1H-pyrazol-1-yl]acetate
-
-
FIX1-47 peptide
-
benzoylphenylalanine containing peptide, 0.038 mM, 50% inhibition
-
Glu-Gly-Arg chloromethylketone
-
heparin
-
in the presence of 0.3 mM bovine pancreatic trypsin inhibitor
methyl (1R)-2-(2-[2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]hydrazino)cyclohexanecarboxylate
-
-
methyl (1S,2R)-2-(2-[(2R)-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]hydrazino)cyclohexanecarboxylate
-
-
methyl (1S,2R)-2-(2-[(2S)-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]hydrazino)cyclohexanecarboxylate
-
-
methyl (1S,2R)-2-(2-[2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]hydrazino)cyclohexanecarboxylate
-
-
methyl 2-([2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxylate
-
-
methyl 2-([2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxylate
-
-
methyl 3-([[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy](phenyl)acetyl]amino)propanoate
-
-
methyl 4-[[(2-carbamimidoyl-1-benzothiophen-6-yl)oxy]methyl]benzoate
-
-
methyl [(2-carbamimidoyl-1-benzothiophen-6-yl)oxy](4-chlorophenyl)acetate
-
-
methyl [(2-carbamimidoyl-1-benzothiophen-6-yl)oxy](4-fluorophenyl)acetate
-
-
N-(2-amino-2-oxoethyl)-2-([2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxamide
-
-
N-(4-[3-([4-(1H-benzimidazol-1-yl)phenyl]amino)-2-(5-carbamimidoyl-1H-indol-3-yl)-3-oxopropyl]phenyl)benzamide
-
-
N-1,3-benzothiazol-5-yl-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanamide
-
-
N-1H-benzimidazol-2-yl-3-([2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanoyl]amino)benzamide
-
-
N-1H-benzimidazol-2-yl-4-([2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanoyl]amino)benzamide
-
-
N-benzyl-2-([2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxamide
-
-
N-benzyl-2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylacetamide
-
-
N-[(3R)-1-(3-amino-4,5-dichloro-1,2-benzoxazol-7-yl)pyrrolidin-3-yl]-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide
-
N-[(3R)-1-(3-amino-4-chloro-1,2-benzoxazol-7-yl)pyrrolidin-3-yl]-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide
-
N-[(3R)-1-(3-amino-4-chloro[1,2]oxazolo[5,4-c]pyridin-7-yl)pyrrolidin-3-yl]-2-chloro-4-(1-methyl-2-oxo-1,2-dihydropyrimidin-5-yl)benzamide
-
N-[(3R)-1-(3-amino-4-chloro[1,2]oxazolo[5,4-c]pyridin-7-yl)pyrrolidin-3-yl]-2-chloro-4-(1-methyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)benzamide
-
N-[(3R)-1-(3-amino-4-chloro[1,2]oxazolo[5,4-c]pyridin-7-yl)pyrrolidin-3-yl]-2-chloro-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzamide
-
N-[(3R)-1-(3-amino-4-chloro[1,2]oxazolo[5,4-c]pyridin-7-yl)pyrrolidin-3-yl]-2-chloro-4-(1H-imidazo[4,5-b]pyridin-1-yl)benzamide
-
N-[(3R)-1-(3-amino-4-chloro[1,2]oxazolo[5,4-c]pyridin-7-yl)pyrrolidin-3-yl]-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
N-[(3R)-1-(3-amino-4-chloro[1,2]oxazolo[5,4-c]pyridin-7-yl)pyrrolidin-3-yl]-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide
-
N-[(3R)-1-(3-amino-4-chloro[1,2]oxazolo[5,4-c]pyridin-7-yl)pyrrolidin-3-yl]-2-chloro-4-(pyrimidin-2-yl)benzamide
-
N-[(3R)-1-(3-amino-4-chloro[1,2]oxazolo[5,4-c]pyridin-7-yl)pyrrolidin-3-yl]-2-chloro-4-(pyrimidin-5-yl)benzamide
-
N-[(3R)-1-(3-amino-4-chloro[1,2]oxazolo[5,4-c]pyridin-7-yl)pyrrolidin-3-yl]-2-chloro-4-[3-(difluoromethyl)-4H-1,2,4-triazol-4-yl]benzamide
-
N-[(3R)-1-(3-amino-4-chloro[1,2]oxazolo[5,4-c]pyridin-7-yl)pyrrolidin-3-yl]-2-chloro-4-[4-(2-hydroxyethyl)-1H-imidazol-1-yl]benzamide
-
N-[(3R)-1-(3-amino-4-chloro[1,2]oxazolo[5,4-c]pyridin-7-yl)pyrrolidin-3-yl]-4-(1H-benzimidazol-1-yl)-2-chlorobenzamide
-
N-[(3R)-1-(3-amino-4-fluoro-1,2-benzoxazol-7-yl)pyrrolidin-3-yl]-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide
-
N-[(3R)-1-(3-amino-5-methyl[1,2]oxazolo[5,4-c]pyridin-7-yl)pyrrolidin-3-yl]-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide
-
N-[(7S)-10-(5-aminopyridin-3-yl)-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide
-
-
N-[1-(3-amino-1,2-benzoxazol-7-yl)pyrrolidin-3-yl]-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide
-
N-[1-(3-amino-5-methyl-1,2-benzoxazol-7-yl)pyrrolidin-3-yl]-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide
-
N-[1-(3-amino[1,2]oxazolo[5,4-c]pyridin-7-yl)pyrrolidin-3-yl]-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide
-
N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
-
N-[4-(1H-benzimidazol-1-yl)-2-fluorophenyl]-2-(5-carbamimidoyl-1-methyl-1H-indol-3-yl)-3-phenylpropanamide
-
-
N-[4-(1H-benzimidazol-1-yl)-2-fluorophenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanamide
-
-
N-[4-(1H-benzimidazol-1-yl)-2-fluorophenyl]-2-(6-carbamimidoyl-1H-indol-1-yl)-3-phenylpropanamide
-
-
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-naphthalen-1-ylpropanamide
-
-
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanamide
-
-
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1-benzothiophen-3-yl)butanamide
-
-
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-2-methylpropanamide
-
-
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-(4-[(phenylsulfonyl)amino]phenyl)propanamide
-
-
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-cyclohexylpropanamide
-
-
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-naphthalen-2-ylpropanamide
-
-
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-pyridin-3-ylpropanamide
-
-
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-4-phenylbutanamide
-
-
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)butanamide
-
-
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)propanamide
-
-
N-[4-(1H-benzimidazol-2-yl)phenyl]-2-benzyl-3-(5-carbamimidoyl-1H-indol-3-yl)propanamide
-
-
N-[4-(1H-benzimidazol-2-yl)phenyl]-3-(5-carbamimidoyl-1H-indol-3-yl)-4-phenylbutanamide
-
-
Na+
200 mM in the absence of Ca2+, 185 mM in the presence of 5 mM Ca2+
PN2-KPI
Kunitz-type inhibitor, competitive, reversible inhibition
-
Polyethylene glycol
-
inhibition with increasing concentration
Rb+
-
slightly inhibiting in presence of Ca2+
recombinant full-length tissue factor pathway inhibitor
-
-
-
supersulfated low molecular weight heparin
-
inhibits the intrinsic tenase (factor IXa-factor VIIIa) complex in an antithrombin-independent manner by 90% when using factor X as substrate. Supersulfated low molecular weight heparin is 32fold more potent than unmodified low molecular weight heparin in the inhibition of factor X activation by the intrinsic tenase complex
-
TFPI-K1
Kunitz-type inhibitor, competitive, reversible inhibition
-
unmodified low molecular weight heparin
-
-
-
[(2-carbamimidoyl-1-benzothiophen-6-yl)oxy](4-fluorophenyl)acetic acid
-
-
antithrombin
-
almost no inhibition in the absence of heparin, strong acceleration of the inhibition rate in the presence of heparin and physiologic levels of Ca2+
-
antithrombin
-
more than 1200fold increase in inhibition in the presence of heparin, 11fold increase in inhibition in the presence of fondaparinux, 7fold increase in inhibition in the presence of 2 mM CaCl2
-
antithrombin
in vivo and in vitro inhibition, the interaction is improved by heparin binding via the formation of bridged complexes where heparin acts as a template
-
antithrombin
-
inactivation, second-order-association rate constants in absence or presence of H5, a pentasaccharide fragment derived from heparin, in a Ca2+-dependent manner, but independent of Na+, overview
-
antithrombin III
-
-
-
antithrombin III
-
a nonspecific protein inhibitor, in presence of heparin, this forms a stable or covalent-like intermediate with the factor IXa
-
EDTA
complete inhibition at 20 mM
EDTA
-
complete inhibition at 20 mM
additional information
-
factor IXa is resistant to inhibition by the plasma inhibitors protein Z-dependent protease inhibitor and tissue factor pathway inhibitor
-
additional information
-
protamine sulfate is able to reverse the heparin effect of the enhanced inhibition with bovine pancreatic trypsin inhibitor
-
additional information
oligosaccharide binding at loop 99 can allosterically modulate the fIXa active site region, overview
-
additional information
-
allosteric activation of antithrombin inhibits factor IXa
-
additional information
-
aptamer 9.3t blocks the activity of factor IXa-factor VIIIa complex
-
additional information
-
factor IXa is resistant to inhibition by the plasma inhibitors protein Z-dependent protease inhibitor and tissue factor pathway inhibitor
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.5 - 8.7
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
1.7 - 3.2
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
2.3
CH3SO2-D-Leu-Gly-L-Arg-p-nitroanilide
-
0.000001 - 0.38
Factor X
-
1.2 - 2.3
L-Leu-Gly-L-Arg-4-nitroanilide
3.62
methoxycarbonyl-D-Nle-Gly-Arg-p-nitroanilide
-
rFIXa, at pH 7.4, in the presence of 33% v/v ethylene glycol
1.43
methylsulfonyl-D-cyclohexylglycyl-Gly-Arg-p-nitroanilide
-
rFIXa, at pH 7.4, in the presence of 33% v/v ethylene glycol
5.99
methylsulfonyl-D-hexahydrotyrosyl-Gly-Arg-p-nitroanilide
-
rFIXa, at pH 7.4, in the presence of 33% v/v ethylene glycol
additional information
additional information
-
0.5
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
wild type enzyme FIXa, in presence of 200 mM Na+
1.9
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
wild type enzyme FIXa
2.1
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
mutant enzyme FIXagamma225P
3.1
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
mutant enzyme FIXagamma225P, in presence of 200 mM Na+
4.5
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
wild type enzyme FIXa, in presence of 5 mM Ca2+ and 185 mM Na+
7.3
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
mutant enzyme FIXagamma225P, in presence of 5 mM Ca2+ and 185 mM Na+
7.9
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
mutant enzyme FIXagamma225P, in presence of 200 mM Ca2+
8.7
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
wild type enzyme FIXa, in presence of 200 mM Ca2+
1.7
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
-
pH 7.5, 22°C, in presence of 5 mM Ca2+ and 0.2 M ChCl
2.2
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
-
pH 7.5, 22°C, in presence of 5 mM Ca2+ with or without presence of 0.2 M LiCl
2.2
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
pH 7.5, 37°C, recombinant wild-type enzyme, in absence of NaCl
2.2
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
pH 7.5, 37°C, recombinant wild-type enzyme, in presence of 0.2 M NaCl
2.3
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
-
pH 7.5, 22°C, in presence of 5 mM Ca2+ and 0.2 M NaCl
3.2
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
-
pH 7.5, 22°C, in presence of 5 mM Ca2+ and 0.2 M RbCl
0.000001
Factor X
-
pH 7.4, 22°C, recombinant mutant N178A the intrinsic tenase complex, in absence of ethylene glycol
-
0.00000311
Factor X
-
chimera enzyme FIXa7omegaloop7EGF2, in the presence of phospholipid vesicles
-
0.0000052
Factor X
-
pH 7.4, 22°C, recombinant mutant R165A the intrinsic tenase complex, in absence of ethylene glycol
-
0.0000068
Factor X
mutant enzyme rFIXa90A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.0000073
Factor X
-
pH 7.4, 22°C, recombinant mutant K126A the intrinsic tenase complex, in absence of ethylene glycol
-
0.0000085
Factor X
-
pH 7.4, 22°C, recombinant mutants N129A and K132A, each in the intrinsic tenase complex, in absence of ethylene glycol
-
0.00000864
Factor X
-
chimera enzyme FIX7EGF2, in the presence of phospholipid vesicles
-
0.0000089
Factor X
mutant enzyme rFIXa107A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.0000096
Factor X
-
pH 7.4, 22°C, recombinant wild-type enzyme the intrinsic tenase complex, in absence of ethylene glycol
-
0.000011
Factor X
-
wild type FIXa, FX activation in presence of FVIIIa
-
0.000013
Factor X
-
mutant Y94F/A95aK/K98T/Y177F/I213V/E219G, FX activation in presence of FVIIIa
-
0.000013
Factor X
-
plasma-derived FIXa, FX activation in presence of FVIIIa
-
0.000014
Factor X
-
mutant Y94F/K98T/Y177F, FX activation in presence of FVIIIa
-
0.000015
Factor X
-
mutant Y94F/K98T, FX activation in presence of FVIIIa
-
0.000016
Factor X
-
37°C, pH 7.4, G94R mutant
-
0.000017
Factor X
-
mutant Y94F/K98T/Y177F/I213V/E219, FX activation in presence of FVIIIa
-
0.0000181
Factor X
mutant enzyme rFIXa90A, 5 units/ml FVIIIa and extruded phosphatidylcholine-phosphatidylserine phospholipid vesicles supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.00002
Factor X
mutant enzyme rFIXa104A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.0000216
Factor X
-
chimera enzyme FIX7EGF2, in the presence of SFLLRN-activated platelets
-
0.0000224
Factor X
mutant enzyme rFIXa94A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.0000251
Factor X
mutant enzyme rFIXa105A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.0000259
Factor X
-
chimera enzyme FIX7omegaloop, in the presence of SFLLRN-activated platelets
-
0.0000286
Factor X
-
chimera enzyme FIX7omegaloop, in the presence of phospholipid vesicles
-
0.00002877
Factor X
-
wild type enzyme, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.0000295
Factor X
mutant enzyme rFIXa91A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.000034
Factor X
mutant enzyme rFIXa107A, 5 units/ml FVIIIa and extruded phosphatidylcholine-phosphatidylserine phospholipid vesicles supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.000037
Factor X
-
25°C, pH 7.4, in the presence of phospholipid vesicle containing 79% phosphatidylcholine, 1% phosphatidylserine and 20% phosphatidylethanolamine
-
0.000038
Factor X
-
FIXa/FXa chimera in which the 39-loop of the protease is replaced with the corresponding loop of FXa, in TBS containing 0.1 mg/ml bovine serum albumin, 0.1% polyethylene glycol (PEG) 8000, and 5 mM Ca2+, at 22°C, pH not specified in the publication
-
0.0000396
Factor X
plasma-derived FIXa, 5 units/ml FVIIIa and extruded phosphatidylcholine-phosphatidylserine phospholipid vesicles supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.00004
Factor X
-
mutant Y94F/K98T/Y177F/I213V/E219, FX activation in absence of FVIIIa
-
0.0000405
Factor X
-
chimera enzyme FIXaN, in the presence of SFLLRN-activated platelets
-
0.0000428
Factor X
plasma-derived FIXa, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.000048
Factor X
-
pH 7.4, 22°C, recombinant mutant K132A the intrinsic tenase complex, in presence of 30% ethylene glycol
-
0.0000502
Factor X
-
chimera enzyme FIXaN, in the presence of phospholipid vesicles
-
0.0000508
Factor X
-
chimera enzyme FIXa7omegaloop7EGF2, in the presence of SFLLRN-activated platelets
-
0.000054
Factor X
-
37°C, pH 7.4
-
0.000055
Factor X
-
pH 7.4, 22°C, recombinant wild-type enzyme the intrinsic tenase complex, in presence of 30% ethylene glycol
-
0.000055
Factor X
-
mutant Y94F/A95aK/K98T/Y177F/I213V/E219G, FX activation in absence of FVIIIa
-
0.00005793
Factor X
-
mutant enzyme E410N, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.000061
Factor X
-
pH 7.4, 22°C, recombinant mutant N129A the intrinsic tenase complex, in presence of 30% ethylene glycol
-
0.0000629
Factor X
mutant enzyme rFIXa91A, 5 units/ml FVIIIa and extruded phosphatidylcholine-phosphatidylserine phospholipid vesicles supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.000064
Factor X
mutant enzyme rFIXa94A, 5 units/ml FVIIIa and extruded phosphatidylcholine-phosphatidylserine phospholipid vesicles supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.000065
Factor X
-
plasma-derived FIXa, FX activation in absence of FVIIIa
-
0.000067
Factor X
-
pH 7.4, 22°C, recombinant mutant R165A the intrinsic tenase complex, in presence of 30% ethylene glycol
-
0.000068
Factor X
-
mutant Y94F/K98T/Y177F, FX activation in absence of FVIIIa
-
0.000068
Factor X
-
wild type FIXa, FX activation in absence of FVIIIa
-
0.00006988
Factor X
-
mutant enzyme E410L, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.000071
Factor X
-
37°C, pH 7.4, R94D mutant
-
0.000071
Factor X
-
wild type enzyme, in TBS containing 0.1 mg/ml bovine serum albumin, 0.1% polyethylene glycol (PEG) 8000, and 5 mM Ca2+, at 22°C, pH not specified in the publication
-
0.0000751
Factor X
-
mutant enzyme E410H, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.0000787
Factor X
mutant enzyme rFIXa104A, 5 units/ml FVIIIa and extruded phosphatidylcholine-phosphatidylserine phospholipid vesicles supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.00008
Factor X
-
variant protein factor IXaAL
-
0.00008
Factor X
-
factor IXabeta', 0.1 mg/ml phospholipids, factor VIIIa in activating mixture
-
0.00008
Factor X
-
pH 7.4, 22°C, recombinant mutant N178A the intrinsic tenase complex, in presence of 30% ethylene glycol
-
0.00008004
Factor X
-
mutant enzyme E410A, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.000083
Factor X
-
mutant Y94F/K98T, FX activation in absence of FVIIIa
-
0.0000869
Factor X
mutant enzyme rFIXa105A, 5 units/ml FVIIIa and extruded phosphatidylcholine-phosphatidylserine phospholipid vesicles supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.000089
Factor X
-
pH 7.4, 22°C, recombinant mutant K126A the intrinsic tenase complex, in presence of 30% ethylene glycol
-
0.00013
Factor X
-
25°C, pH 7.4, in the presence of GIGAVLKVLTTGLPALISSWIKRKRQQ
-
0.0001542
Factor X
mutant enzyme rFIXa89A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
0.00017
Factor X
-
factor IXabeta', 0.1 mg/ml phospholipids in activating mixture
-
0.00017
Factor X
-
25°C, pH 7.4, in the presence of TRYLRIHPQSWVHQIALRMEV
-
0.00018
Factor X
-
variant protein factor IXaCH
-
0.0002227
Factor X
-
mutant enzyme E410N, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.0002241
Factor X
-
mutant enzyme E410A, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.000231
Factor X
-
mutant enzyme E410H, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.0002328
Factor X
-
mutant enzyme E410L, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.0004478
Factor X
-
wild type enzyme, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.0006
Factor X
-
Gla-domainless factor IXabeta', 0.1 mg/ml phospholipids, factor VIIIa in activating mixture
-
0.00063
Factor X
in the presence of 0.1 mM phospholipid and 5 mM Ca2+
-
0.0008
Factor X
-
Gla-domainless factor IXabeta', 0.1 mg/ml phospholipids in activating mixture
-
0.001
Factor X
-
Gla-domainless factor IXabeta' in activating mixture
-
0.0045
Factor X
-
in the presence of recombinant tissue factor protein and vesicles composed of 75% (w/w) L-alpha-phosphatidylcholine and 25% (w/w) L-alpha-phosphatidylserine
-
0.0239
Factor X
-
factor IXabeta' in activating mixture
-
0.095
Factor X
-
25°C, pH 7.4
-
0.3
Factor X
-
FIXa, in the absence of platelet surface
-
0.38
Factor X
-
25°C, pH 7.4, in the presence of phospholipid vesicle containing 79% phosphatidylcholine, 1% phosphatidylserine and 20% phosphatidylethanolamine
-
1.2
L-Leu-Gly-L-Arg-4-nitroanilide
-
FIXa/FXa chimera in which the 39-loop of the protease is replaced with the corresponding loop of FXa, in 0.02 M Tris-HCl (pH 7.5) buffer containing 0.1 M NaCl, 0.1 mg/ml bovine serum albumin, 33% ethylene glycol, and 5 mM Ca2+, at 22°C
2.3
L-Leu-Gly-L-Arg-4-nitroanilide
-
wild type enzyme, in 0.02 M Tris-HCl (pH 7.5) buffer containing 0.1 M NaCl, 0.1 mg/ml bovine serum albumin, 33% ethylene glycol, and 5 mM Ca2+, at 22°C
additional information
additional information
-
kinetic determination of the affinity for factor IXa-factor VIIIa complex formation, effect of ethylene glycol at 30% on reaction kinetics, overview
-
additional information
additional information
steady-state kinetics of wild-type and mutant enzymes n presence or absence of NaCl
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.005 - 3.38
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
18.5 - 21.9
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
13.2
CH3SO2-D-Leu-Gly-L-Arg-p-nitroanilide
-
0.00011 - 1999
Factor X
-
17.5 - 21.4
L-Leu-Gly-L-Arg-4-nitroanilide
2.01
methoxycarbonyl-D-Nle-Gly-Arg-p-nitroanilide
-
rFIXa, at pH 7.4, in the presence of 33% v/v ethylene glycol
5.67
methylsulfonyl-D-cyclohexylglycyl-Gly-Arg-p-nitroanilide
-
rFIXa, at pH 7.4, in the presence of 33% v/v ethylene glycol
6.11
methylsulfonyl-D-hexahydrotyrosyl-Gly-Arg-p-nitroanilide
-
rFIXa, at pH 7.4, in the presence of 33% v/v ethylene glycol
additional information
2-[5-Amino-2-(4-fluoro-phenyl)-6-oxo-6H-pyrimidin-1-yl]-N-(1-benzyl-2-oxo-2-thiazol-2-yl-ethyl)-acetamide
0.005
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
mutant enzyme FIXagamma225P
0.058
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
mutant enzyme FIXagamma225P, in presence of 200 mM Na+
0.42
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
wild type enzyme FIXa
0.63
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
wild type enzyme FIXa, in presence of 200 mM Na+
0.78
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
mutant enzyme FIXagamma225P, in presence of Ca2+ and 185 mM Na+
0.89
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
mutant enzyme FIXagamma225P, in presence of 200 mM Ca2+
3.15
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
wild type enzyme FIXa, in presence of 200 mM Ca2+
3.38
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
wild type enzyme FIXa, in presence of Ca2+ and 185 mM Na+
18.5
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
-
pH 7.5, 22°C, in presence of 5 mM Ca2+
18.5
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
pH 7.5, 37°C, recombinant wild-type enzyme, in absence of NaCl
19
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
-
pH 7.5, 22°C, in presence of 5 mM Ca2+ and 0.2 M LiCl
20.2
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
-
pH 7.5, 22°C, in presence of 5 mM Ca2+ and 0.2 M NaCl
20.2
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
pH 7.5, 37°C, recombinant wild-type enzyme, in presence of 0.2 M NaCl
21.3
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
-
pH 7.5, 22°C, in presence of 5 mM Ca2+ and 0.2 M ChCl
21.9
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
-
pH 7.5, 22°C, in presence of 5 mM Ca2+ and 0.2 M RbCl
0.00011
Factor X
-
mutant Y94F/K98T/Y177F, FX activation in presence of FVIIIa
-
0.00016
Factor X
-
25°C, pH 7.4
-
0.00017
Factor X
-
wild type FIXa, FX activation in presence of FVIIIa
-
0.0002
Factor X
-
mutant Y94F/A95aK/K98T/Y177F/I213V/E219G, FX activation in presence of FVIIIa
-
0.00021
Factor X
-
plasma-derived FIXa, FX activation in absence of FVIIIa
-
0.00022
Factor X
-
plasma-derived FIXa, FX activation in presence of FVIIIa
-
0.00023
Factor X
-
25°C, pH 7.4, in the presence of GIGAVLKVLTTGLPALISSWIKRKRQQ
-
0.00025
Factor X
-
25°C, pH 7.4, in the presence of TRYLRIHPQSWVHQIALRMEV
-
0.00029
Factor X
-
wild type FIXa, FX activation in absence of FVIIIa
-
0.0003
Factor X
-
mutant Y94F/K98T, FX activation in presence of FVIIIa
-
0.00033
Factor X
-
mutant Y94F/K98T/Y177F, FX activation in absence of FVIIIa
-
0.00059
Factor X
-
mutant Y94F/K98T, FX activation in absence of FVIIIa
-
0.00088
Factor X
-
mutant Y94F/K98T/Y177F/I213V/E219, FX activation in presence of FVIIIa
-
0.00096
Factor X
-
mutant enzyme E410H, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.00096
Factor X
-
mutant enzyme E410N, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.001
Factor X
in the presence of 0.1 mM phospholipid and 5 mM Ca2+
-
0.001
Factor X
-
mutant Y94F/A95aK/K98T/Y177F/I213V/E219G, FX activation in absence of FVIIIa
-
0.00105
Factor X
-
mutant enzyme E410A, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.0012
Factor X
-
mutant enzyme E410L, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.00127
Factor X
-
wild type enzyme, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.00157
Factor X
-
wild type enzyme, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.002
Factor X
-
FIXa, in the absence of platelet surface
-
0.0022
Factor X
-
mutant Y94F/K98T/Y177F/I213V/E219, FX activation in absence of FVIIIa
-
0.00248
Factor X
-
mutant enzyme E410N, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.00361
Factor X
-
mutant enzyme E410L, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.00397
Factor X
-
mutant enzyme E410H, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.00399
Factor X
-
mutant enzyme E410A, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.048
Factor X
-
in the presence of emicizumab, pH and temperature not specified in the publication
-
0.38
Factor X
-
25°C, pH 7.4, in the presence of phospholipid vesicle containing 79% phosphatidylcholine, 1% phosphatidylserine and 20% phosphatidylethanolamine
-
1
Factor X
-
FIXa/FXa chimera in which the 39-loop of the protease is replaced with the corresponding loop of FXa, in TBS containing 0.1 mg/ml bovine serum albumin, 0.1% polyethylene glycol (PEG) 8000, and 5 mM Ca2+, at 22°C, pH not specified in the publication
-
1.9
Factor X
-
pH 7.4, 22°C, recombinant mutant R165A the intrinsic tenase complex, in absence of ethylene glycol
-
2.1
Factor X
-
in the presence of factor VIIIa, pH and temperature not specified in the publication
-
2.9
Factor X
mutant enzyme rFIXa104A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
2.9
Factor X
mutant enzyme rFIXa94A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
3.2
Factor X
-
chimera enzyme FIXaN, in the presence of SFLLRN-activated platelets
-
3.3
Factor X
-
chimera enzyme FIX7EGF2, in the presence of SFLLRN-activated platelets
-
3.3
Factor X
mutant enzyme rFIXa107A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
3.4
Factor X
plasma-derived FIXa, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
3.5
Factor X
-
wild type enzyme, in TBS containing 0.1 mg/ml bovine serum albumin, 0.1% polyethylene glycol (PEG) 8000, and 5 mM Ca2+, at 22°C, pH not specified in the publication
-
3.8
Factor X
-
chimera enzyme FIX7omegaloop, in the presence of SFLLRN-activated platelets
-
3.8
Factor X
mutant enzyme rFIXa105A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
4.1
Factor X
mutant enzyme rFIXa90A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
5.08
Factor X
-
pH 7.4, 22°C, recombinant mutant N178A the intrinsic tenase complex, in absence of ethylene glycol
-
5.2
Factor X
mutant enzyme rFIXa91A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
5.2
Factor X
-
pH 7.4, 22°C, recombinant mutant K126A the intrinsic tenase complex, in absence of ethylene glycol
-
5.47
Factor X
-
pH 7.4, 22°C, recombinant mutant K132A the intrinsic tenase complex, in absence of ethylene glycol
-
5.51
Factor X
-
pH 7.4, 22°C, recombinant wild-type enzyme the intrinsic tenase complex, in absence of ethylene glycol
-
5.6
Factor X
-
pH 7.4, 22°C, recombinant mutant N129A the intrinsic tenase complex, in absence of ethylene glycol
-
12.3
Factor X
-
factor IXaAL
-
16.6
Factor X
mutant enzyme rFIXa89A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
20.8
Factor X
-
factor IXaCH
-
43.9
Factor X
-
factor IXaAL, platelet-bound
-
110
Factor X
-
factor IXaCH , platelet-bound
-
600
Factor X
-
pH 7.4, 22°C, recombinant mutant N178A the intrinsic tenase complex, in presence of 30% ethylene glycol
-
1000
Factor X
-
pH 7.4, 22°C, recombinant mutant R165A the intrinsic tenase complex, in presence of 30% ethylene glycol
-
1340
Factor X
-
pH 7.4, 22°C, recombinant wild-type enzyme and mutant N129A, each in the intrinsic tenase complex, in presence of 30% ethylene glycol
-
1780
Factor X
-
pH 7.4, 22°C, recombinant mutant K132A the intrinsic tenase complex, in presence of 30% ethylene glycol
-
1999
Factor X
-
pH 7.4, 22°C, recombinant mutant K126A the intrinsic tenase complex, in presence of 30% ethylene glycol
-
17.5
L-Leu-Gly-L-Arg-4-nitroanilide
-
FIXa/FXa chimera in which the 39-loop of the protease is replaced with the corresponding loop of FXa, in 0.02 M Tris-HCl (pH 7.5) buffer containing 0.1 M NaCl, 0.1 mg/ml bovine serum albumin, 33% ethylene glycol, and 5 mM Ca2+, at 22°C
21.4
L-Leu-Gly-L-Arg-4-nitroanilide
-
wild type enzyme, in 0.02 M Tris-HCl (pH 7.5) buffer containing 0.1 M NaCl, 0.1 mg/ml bovine serum albumin, 33% ethylene glycol, and 5 mM Ca2+, at 22°C
additional information
2-[5-Amino-2-(4-fluoro-phenyl)-6-oxo-6H-pyrimidin-1-yl]-N-(1-benzyl-2-oxo-2-thiazol-2-yl-ethyl)-acetamide
-
the catalytic efficiency kcat/Km, of phospholipid vesicles containing 20 or 35% phosphatidylethanolamine and no phosphatidylserine is 5.5fold higher than that of vesicles containing 1% phosphatidylserine and no phosphatidylethanolamine
additional information
additional information
-
the catalytic efficiency kcat/Km, of phospholipid vesicles containing 20 or 35% phosphatidylethanolamine and no phosphatidylserine is 5.5fold higher than that of vesicles containing 1% phosphatidylserine and no phosphatidylethanolamine
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0005
(2-carbamimidoylbenzo[b]thiophen-4-yloxy)phenylacetic acid methyl ester
-
pH and temperature not specified in the publication
0.000003
(2-carbamimidoylbenzo[b]thiophen-6-yloxy)thiophen-2-ylacetic acid ethyl ester
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0000008
(2E)-3-[(7S)-7-[2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamido]-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]prop-2-enoic acid
-
pH and temperature not specified in the publication
0.00048
(2R)-N-1,3-benzothiazol-5-yl-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanamide
-
-
0.000018
(2R)-N-[4-(1H-benzimidazol-1-yl)-2-fluorophenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanamide
-
-
0.01422
(2S)-N-1,3-benzothiazol-5-yl-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanamide
-
-
0.00082
(2S)-N-[4-(1H-benzimidazol-1-yl)-2-fluorophenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanamide
-
-
0.0000006
(7S)-2-methyl-7-phenyl-7-[4-(4H-1,2,4-triazol-4-yl)benzamido]-6,7,8,9-tetrahydropyrido[1,2-a]indole-10-carboxylic acid
-
pH and temperature not specified in the publication
0.0000025
(7S)-2-methyl-7-phenyl-7-[[5-(4H-1,2,4-triazol-4-yl)pyridine-2-carbonyl]amino]-6,7,8,9-tetrahydropyrido[1,2-a]indole-10-carboxylic acid
-
pH and temperature not specified in the publication
0.0000086
(7S)-7-[2-chloro-4-(1H-tetrazol-1-yl)benzamido]-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indole-10-carboxylic acid
-
pH and temperature not specified in the publication
0.0000006
(7S)-7-[2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamido]-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indole-10-carboxylic acid
-
pH and temperature not specified in the publication
0.0000012
(7S)-7-[2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamido]-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indole-10-carboxamide
-
pH and temperature not specified in the publication
0.0000063 - 0.0000348
1-(3-chloro-4-[[(2R)-2,8-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]carbamoyl]phenyl)-1H-benzimidazole-5-carboxylic acid
0.0000045
2,6-dichloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)-N-[(2R)-8-methyl-2-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]benzamide
-
pH and temperature not specified in the publication
0.0000125
2,6-dichloro-N-((R)-2-((S)-1-hydroxyethyl)-8-methyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000102 - 0.0000121
2,6-dichloro-N-[(2R)-10-hydroxy-2,7-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
0.0000102
2,6-dichloro-N-[(2R)-2,8-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000105
2,6-dichloro-N-[(2R)-2-(3,4-difluorophenyl)-8-methyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000031 - 0.0000066
2,6-dichloro-N-[(2R)-2-(3-fluorophenyl)-8-methyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
0.0000042
2,6-dichloro-N-[(2R)-2-(4-fluorophenyl)-8-methyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000018
2,6-dichloro-N-[(2R)-8-methyl-2-(3-methylphenyl)-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.000005
2,6-dichloro-N-[(2R)-8-methyl-2-[1-(propan-2-yl)-1H-1,2,3-triazol-4-yl]-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000117 - 0.0002676
2,6-dichloro-N-[(3R)-3,7-dimethyl-2,3,4,9-tetrahydro-1H-carbazol-3-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
0.00515
2-(2-carbamimidoylbenzo[b]thiophen-4-yloxy)propionic acid methyl ester
-
pH and temperature not specified in the publication
0.0001
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenyl-N-(4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl)propanamide
-
-
0.00039
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenyl-N-[4-(4-phenyl-1H-imidazol-1-yl)phenyl]propanamide
-
-
0.00173
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-N-(4-cyanophenyl)-3-phenylpropanamide
-
-
0.00058
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-N-(4-methylphenyl)-3-phenylpropanamide
-
-
0.00025
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-N-(4-phenoxyphenyl)-3-phenylpropanamide
-
-
0.00093
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-N-(4-[(6-chloropyridazin-3-yl)sulfamoyl]phenyl)-3-phenylpropanamide
-
-
0.0096
2-(5-carbamimidoyl-1-benzothiophen-3-yl)-N-(5-fluoro-2-methylphenyl)-3-phenylpropanamide
-
-
0.00066
2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenyl-N-(2'-sulfamoylbiphenyl-4-yl)propanamide
-
-
0.00027
2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenyl-N-[4-(5-phenyl-1H-imidazol-4-yl)phenyl]propanamide
-
-
0.0067
2-(5-carbamimidoyl-1H-indol-3-yl)-N-(2'-sulfamoylbiphenyl-4-yl)acetamide
-
-
0.00031
2-(5-carbamimidoyl-1H-indol-3-yl)-N-(4-ethylphenyl)-3-phenylpropanamide - 1H-benzimidazole
-
(1:1)
0.00024
2-(7-carbamimidoylnaphthalen-1-yl)-N-[2-(1-ethoxyethenyl)cyclohexyl]-3-phenylpropanamide
-
-
0.00043
2-([2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)-N-ethylcyclohexanecarboxamide
-
-
0.0035
2-([2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxylic acid
-
-
0.00095
2-amidino-4-iodobenzothiophene
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.000003
2-chloro-N-[(2R)-2-(3-methoxyphenyl)-8-methyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000021 - 0.0000069
2-chloro-N-[(2R)-8-methyl-2-phenyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
0.0000051 - 0.0000084
2-chloro-N-[(7S)-10-cyclopropyl-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
0.0000024 - 0.0000029
2-chloro-N-[(7S)-10-[(E)-(hydroxyimino)methyl]-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
0.0000026 - 0.0000055
2-chloro-N-[(7S)-2-methyl-7-phenyl-10-(2,2,2-trifluoro-1-hydroxyethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
0.0000024
2-chloro-N-[(7S)-2-methyl-7-phenyl-10-(2H-tetrazol-5-yl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
pH and temperature not specified in the publication
0.00029
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenyl-N-[4-(pyrrolidin-1-ylcarbonyl)phenyl]acetamide
-
pH and temperature not specified in the publication
0.00001
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (1,3-dimethyl-1H-pyrazol-5-yl)carbamate
-
pH and temperature not specified in the publication
0.000007
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (2,4-difluorophenyl)carbamate
-
pH and temperature not specified in the publication
0.000007
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (2,6-difluorophenyl)carbamate
-
pH and temperature not specified in the publication
0.000005
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (2-fluorophenyl)carbamate
-
pH and temperature not specified in the publication
0.000008
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (2-methylphenyl)carbamate
-
pH and temperature not specified in the publication
0.000002
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (2-[[(2-methylpropyl)amino]methyl]phenyl)carbamate
-
pH and temperature not specified in the publication
0.000012
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (3,5-dimethyl-1,2-oxazol-4-yl)carbamate
-
pH and temperature not specified in the publication
0.000008
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (3,5-dimethyl-1H-pyrazol-4-yl)carbamate
-
pH and temperature not specified in the publication
0.000025
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (3-fluorophenyl)carbamate
-
pH and temperature not specified in the publication
0.000008
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (4-fluorophenyl)carbamate
-
pH and temperature not specified in the publication
0.000005
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl (4-methoxyphenyl)carbamate
-
pH and temperature not specified in the publication
0.00001
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl phenylcarbamate
-
pH and temperature not specified in the publication
0.000003
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [1,3-dimethyl-5-[(propan-2-ylamino)methyl]-1H-pyrazol-4-yl]carbamate
-
pH and temperature not specified in the publication
0.000005
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [1-methyl-3-[(methylamino)methyl]-1H-pyrazol-5-yl]carbamate
-
pH and temperature not specified in the publication
0.000004
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [2-(aminomethyl)phenyl]carbamate
-
pH and temperature not specified in the publication
0.000003
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [2-(piperazin-1-ylmethyl)phenyl]carbamate
-
pH and temperature not specified in the publication
0.000008
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [2-[(dimethylamino)methyl]phenyl]carbamate
-
pH and temperature not specified in the publication
0.000003
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [2-[(methylamino)methyl]phenyl]carbamate
-
pH and temperature not specified in the publication
0.000009
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbamate
-
pH and temperature not specified in the publication
0.00001
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [4-[(4-methylpiperazin-1-yl)methyl]phenyl]carbamate
-
pH and temperature not specified in the publication
0.000004
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [4-[2-(dimethylamino)ethoxy]phenyl]carbamate
-
pH and temperature not specified in the publication
0.000005
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl [5-[(ethylamino)methyl]-1,3-dimethyl-1H-pyrazol-4-yl]carbamate
-
pH and temperature not specified in the publication
0.00017
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-N,2-diphenylacetamide
-
pH and temperature not specified in the publication
0.00014
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-N-(2-methoxyphenyl)-2-phenylacetamide
-
pH and temperature not specified in the publication
0.00013
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-N-(3-methoxyphenyl)-2-phenylacetamide
-
pH and temperature not specified in the publication
0.00014
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-N-(4-methoxyphenyl)-2-phenylacetamide
-
pH and temperature not specified in the publication
0.001
2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-N-[2-(dimethylamino)ethyl]-2-phenylacetamide
-
pH and temperature not specified in the publication
0.00198
2-[(2-carbamimidoyl-1-benzothiophen-6-yl)oxy]-2-(4-fluorophenyl)acetamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0000155
2-[(2-carbamimidoyl-6-fluoro-1-benzothiophen-4-yl)oxy]-2-phenylethyl phenylcarbamate
-
pH and temperature not specified in the publication
0.0000044
2-[(2-carbamimidoyl-6-fluoro-1-benzothiophen-4-yl)oxy]-2-phenylethyl [2-(aminomethyl)phenyl]carbamate
-
pH and temperature not specified in the publication
0.0000081
2-[(2-carbamimidoyl-6-fluoro-1-benzothiophen-4-yl)oxy]-2-phenylethyl [2-[(dimethylamino)methyl]phenyl]carbamate
-
pH and temperature not specified in the publication
0.0049
3-(1-[4-(1H-benzimidazol-1-yl)phenyl]-2-oxopyrrolidin-3-yl)-1-benzothiophene-5-carboximidamide
-
-
0.000028
3-(2-carbamimidoylbenzo[b]thiophen-6-yloxy)-3-(4-chlorophenyl)propionic acid methyl ester
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.000063
3-(2-[4-(1H-benzimidazol-1-yl)phenyl]-1-benzyl-2-oxoethyl)-1-benzothiophene-5-carboximidamide
-
-
0.000074
3-(4-aminophenyl)-N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1-benzothiophen-3-yl)propanamide
-
-
0.000075
3-(4-aminophenyl)-N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)propanamide
-
-
0.0000027 - 0.0000138
3-[(7R)-7-[2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamido]-2-methyl-7-phenyl-4a,6,7,8,9,10a-hexahydropyrido[1,2-a]indol-10-yl]propanoic acid
0.000059
3-[3-([4-(1H-benzimidazol-1-yl)phenyl]amino)-2-(5-carbamimidoyl-1H-indol-3-yl)-3-oxopropyl]benzoic acid
-
-
0.00066
4-(([2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanoyl]amino)methyl)-N-[5-(methylsulfonyl)-1H-benzimidazol-2-yl]benzamide
-
-
0.000036
4-(2-carbamimidoylbenzo[b]thiophen-6-yloxy)-4-(4-chlorophenyl) butyric acid methyl ester
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0015
4-(benzyloxy)-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.00037
4-([[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy](phenyl)acetyl]amino)-N,N-dimethylbenzamide
-
pH and temperature not specified in the publication
2
4-cyano-2-fluoro-N-(10-hydroxy-2,7-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl)benzamide
-
pH and temperature not specified in the publication
0.0016
4-phenyl-1-benzothiophene-2-sulfinimidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.00027
4-[phenyl(3-phenyl[1,2,4]oxadiazol-5-yl)methoxy]benzo[b]thiophene-2-carboxamidine
-
pH and temperature not specified in the publication
0.0059
5-(3,4-dimethoxyphenyl)benzo[b]thiophene-2-carboxamidine
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0019
5-(benzyloxy)-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.008
5-phenyl-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0216
6-(2-phenylethoxy)-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0008 - 0.0242
6-(3,4-dimethoxyphenyl)-1-benzothiophene-2-carboximidamide
0.000031
6-(3-chloro-4-fluorobenzyloxy)benzo[b]thiophene-2-carboxamidine
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.00035
6-(pyridin-3-ylmethoxy)-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.00035
6-(thiophen-2-ylmethoxy)benzo[b]thiophene-2-carboxamidine
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0038
6-benzyloxybenzo[b]thiophene-2-carboxamidine
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0072
6-[(2-chlorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.023
6-[(2-fluorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0269
6-[(2-methoxybenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.00045
6-[(3,4-difluorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0009
6-[(3-chlorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.00068
6-[(3-fluorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.00045
6-[(3-methoxybenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.000075
6-[(4-chloro-3-fluorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.00045
6-[(4-chlorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0007
6-[(4-fluorobenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.00025
6-[(4-methoxybenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0009
6-[(4-methylbenzyl)oxy]-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0113
6-[1-(4-fluorophenyl)ethoxy]-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.037 - 0.7
Bovine pancreatic trypsin inhibitor
-
0.00042
ethyl 1-[4-([[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy](phenyl)acetyl]amino)phenyl]-1H-imidazole-2-carboxylate
-
pH and temperature not specified in the publication
0.00853
ethyl 2-([2-(5-carbamimidoyl-1,1-dioxido-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxylate
-
-
0.0019
ethyl 2-([2-(5-carbamimidoyl-1-benzofuran-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxylate
-
-
0.00012
ethyl 2-([2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxylate
-
-
0.0119
ethyl [(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]acetate
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0038
ethyl [(2-carbamimidoyl-1-benzothiophen-6-yl)oxy]acetate
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.000011
ethyl [4-[([2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethoxy]carbonyl)amino]-3,5-dimethyl-1H-pyrazol-1-yl]acetate
-
pH and temperature not specified in the publication
0.0005
methyl (1R)-2-(2-[2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]hydrazino)cyclohexanecarboxylate
-
-
0.00028
methyl (1S,2R)-2-(2-[(2R)-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]hydrazino)cyclohexanecarboxylate
-
-
0.0413
methyl (1S,2R)-2-(2-[(2S)-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]hydrazino)cyclohexanecarboxylate
-
-
0.00031
methyl (1S,2R)-2-(2-[2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]hydrazino)cyclohexanecarboxylate
-
-
0.00014
methyl 2-([2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxylate
-
-
0.00034
methyl 2-([2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxylate
-
-
0.0084
methyl 3-([[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy](phenyl)acetyl]amino)propanoate
-
pH and temperature not specified in the publication
0.0113
methyl 4-[[(2-carbamimidoyl-1-benzothiophen-6-yl)oxy]methyl]benzoate
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.00002
methyl [(2-carbamimidoyl-1-benzothiophen-6-yl)oxy](4-chlorophenyl)acetate
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.00004
methyl [(2-carbamimidoyl-1-benzothiophen-6-yl)oxy](4-fluorophenyl)acetate
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.00028
N-(2-amino-2-oxoethyl)-2-([2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxamide
-
-
0.00027
N-(4-[3-([4-(1H-benzimidazol-1-yl)phenyl]amino)-2-(5-carbamimidoyl-1H-indol-3-yl)-3-oxopropyl]phenyl)benzamide
-
-
0.00078
N-1,3-benzothiazol-5-yl-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanamide
-
-
0.0019
N-1H-benzimidazol-2-yl-3-([2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanoyl]amino)benzamide
-
-
0.00093
N-1H-benzimidazol-2-yl-4-([2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanoyl]amino)benzamide
-
-
0.032
N-benzyl-2-([2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanoyl]amino)cyclohexanecarboxamide
-
-
0.00039
N-benzyl-2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylacetamide
-
pH and temperature not specified in the publication
0.0000016
N-[(7S)-10-(5-aminopyridin-3-yl)-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide
-
pH and temperature not specified in the publication
9
N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
pH and temperature not specified in the publication
0.00036
N-[4-(1H-benzimidazol-1-yl)-2-fluorophenyl]-2-(5-carbamimidoyl-1-methyl-1H-indol-3-yl)-3-phenylpropanamide
-
-
0.000063
N-[4-(1H-benzimidazol-1-yl)-2-fluorophenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-phenylpropanamide
-
-
0.0003
N-[4-(1H-benzimidazol-1-yl)-2-fluorophenyl]-2-(6-carbamimidoyl-1H-indol-1-yl)-3-phenylpropanamide
-
-
0.00023
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-naphthalen-1-ylpropanamide
-
-
0.000098
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1-benzothiophen-3-yl)-3-phenylpropanamide
-
-
0.00024
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1-benzothiophen-3-yl)butanamide
-
-
0.00075
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-2-methylpropanamide
-
-
0.00013
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-(4-[(phenylsulfonyl)amino]phenyl)propanamide
-
-
0.0038
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-cyclohexylpropanamide
-
-
0.000098
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-naphthalen-2-ylpropanamide
-
-
0.0012
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-3-pyridin-3-ylpropanamide
-
-
0.00024
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)-4-phenylbutanamide
-
-
0.00016
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)butanamide
-
-
0.00048
N-[4-(1H-benzimidazol-1-yl)phenyl]-2-(5-carbamimidoyl-1H-indol-3-yl)propanamide
-
-
0.00013
N-[4-(1H-benzimidazol-2-yl)phenyl]-2-benzyl-3-(5-carbamimidoyl-1H-indol-3-yl)propanamide
-
-
0.00025
N-[4-(1H-benzimidazol-2-yl)phenyl]-3-(5-carbamimidoyl-1H-indol-3-yl)-4-phenylbutanamide
-
-
0.0000025 - 0.00017
supersulfated low molecular weight heparin
-
0.00001 - 0.00147
unmodified low molecular weight heparin
-
0.000021
[(2-carbamimidoyl-1-benzothiophen-6-yl)oxy](4-fluorophenyl)acetic acid
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
additional information
additional information
inhibition kinetics
-
0.0000063
1-(3-chloro-4-[[(2R)-2,8-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]carbamoyl]phenyl)-1H-benzimidazole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0000105
1-(3-chloro-4-[[(2R)-2,8-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]carbamoyl]phenyl)-1H-benzimidazole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0000348
1-(3-chloro-4-[[(2R)-2,8-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]carbamoyl]phenyl)-1H-benzimidazole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0000102
2,6-dichloro-N-[(2R)-10-hydroxy-2,7-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000121
2,6-dichloro-N-[(2R)-10-hydroxy-2,7-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000031
2,6-dichloro-N-[(2R)-2-(3-fluorophenyl)-8-methyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000066
2,6-dichloro-N-[(2R)-2-(3-fluorophenyl)-8-methyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000117
2,6-dichloro-N-[(3R)-3,7-dimethyl-2,3,4,9-tetrahydro-1H-carbazol-3-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0002676
2,6-dichloro-N-[(3R)-3,7-dimethyl-2,3,4,9-tetrahydro-1H-carbazol-3-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000021
2-chloro-N-[(2R)-8-methyl-2-phenyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000059
2-chloro-N-[(2R)-8-methyl-2-phenyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000069
2-chloro-N-[(2R)-8-methyl-2-phenyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
-
pH and temperature not specified in the publication
0.0000051
2-chloro-N-[(7S)-10-cyclopropyl-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
pH and temperature not specified in the publication
0.000008
2-chloro-N-[(7S)-10-cyclopropyl-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
pH and temperature not specified in the publication
0.0000084
2-chloro-N-[(7S)-10-cyclopropyl-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
pH and temperature not specified in the publication
0.0000024
2-chloro-N-[(7S)-10-[(E)-(hydroxyimino)methyl]-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
pH and temperature not specified in the publication
0.0000029
2-chloro-N-[(7S)-10-[(E)-(hydroxyimino)methyl]-2-methyl-7-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
pH and temperature not specified in the publication
0.0000026
2-chloro-N-[(7S)-2-methyl-7-phenyl-10-(2,2,2-trifluoro-1-hydroxyethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
pH and temperature not specified in the publication
0.0000055
2-chloro-N-[(7S)-2-methyl-7-phenyl-10-(2,2,2-trifluoro-1-hydroxyethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide
-
pH and temperature not specified in the publication
0.0000027
3-[(7R)-7-[2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamido]-2-methyl-7-phenyl-4a,6,7,8,9,10a-hexahydropyrido[1,2-a]indol-10-yl]propanoic acid
-
pH and temperature not specified in the publication
0.0000138
3-[(7R)-7-[2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamido]-2-methyl-7-phenyl-4a,6,7,8,9,10a-hexahydropyrido[1,2-a]indol-10-yl]propanoic acid
-
pH and temperature not specified in the publication
0.0008
6-(3,4-dimethoxyphenyl)-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.0242
6-(3,4-dimethoxyphenyl)-1-benzothiophene-2-carboximidamide
-
in 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.5% (w/v) PEG6000 (pH 7.4), at 22°C
0.037
Bovine pancreatic trypsin inhibitor
-
in the presence of heparin
-
0.07
Bovine pancreatic trypsin inhibitor
-
in the presence of enoxaparin
-
0.7
Bovine pancreatic trypsin inhibitor
-
in the absence of heparin
-
0.025
Na+
wild type enzyme FIXa, in the presence of 200 mM Na+
0.099
Na+
wild type enzyme FIXa
0.119
Na+
wild type enzyme FIXa, in the presence of 185 mM Na+ and 5 mM Ca2+
0.166
Na+
wild type enzyme FIXa, in the presence of 5 mM Ca2+
0.179
Na+
mutant enzyme FIXagamma225P, in the presence of 185 mM Na+ and 5 mM Ca2+
0.184
Na+
mutant enzyme FIXagamma225P, in the presence of 5 mM Ca2+
0.813
Na+
mutant enzyme FIXagamma225P, in the presence of 200 mM Na+
0.0000025
supersulfated low molecular weight heparin
-
mutant enzyme R170A, using factor X as substrate, at pH 7.4, 22°C
-
0.000003
supersulfated low molecular weight heparin
-
wild type enzyme, using factor X as substrate, at pH 7.4, 22°C
-
0.0000039
supersulfated low molecular weight heparin
-
mutant enzyme N178A, using factor X as substrate, at pH 7.4, 22°C
-
0.0000042
supersulfated low molecular weight heparin
-
mutant enzyme N129A, using factor X as substrate, at pH 7.4, 22°C
-
0.00001
supersulfated low molecular weight heparin
-
mutant enzyme K132A, using factor X as substrate, at pH 7.4, 22°C
-
0.000017
supersulfated low molecular weight heparin
-
mutant enzyme R165A, using factor X as substrate, at pH 7.4, 22°C
-
0.000072
supersulfated low molecular weight heparin
-
mutant enzyme K126A, using factor X as substrate, at pH 7.4, 22°C
-
0.00017
supersulfated low molecular weight heparin
-
mutant enzyme R233A, using factor X as substrate, at pH 7.4, 22°C
-
0.00001
unmodified low molecular weight heparin
-
mutant enzyme N129A, using factor X as substrate, at pH 7.4, 22°C
-
0.000012
unmodified low molecular weight heparin
-
mutant enzyme R170A, using factor X as substrate, at pH 7.4, 22°C
-
0.000012
unmodified low molecular weight heparin
-
wild type enzyme, using factor X as substrate, at pH 7.4, 22°C
-
0.0000141
unmodified low molecular weight heparin
-
mutant enzyme N178A, using factor X as substrate, at pH 7.4, 22°C
-
0.000049
unmodified low molecular weight heparin
-
mutant enzyme K132A, using factor X as substrate, at pH 7.4, 22°C
-
0.00016
unmodified low molecular weight heparin
-
mutant enzyme R165A, using factor X as substrate, at pH 7.4, 22°C
-
0.00032
unmodified low molecular weight heparin
-
mutant enzyme K126A, using factor X as substrate, at pH 7.4, 22°C
-
0.00147
unmodified low molecular weight heparin
-
mutant enzyme R233A, using factor X as substrate, at pH 7.4, 22°C
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Fujikawa, K.; Legaz, M.E.; Kato, H.; Davie, E.W.
The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa (activated plasma thromboplastin antecedent)
Biochemistry
13
4508-4516
1974
Bos taurus
brenda
Thompson, A.R.
Structure, function and molecular defects of factor IX
Blood
67
565-572
1986
Homo sapiens
brenda
Van Dieijen, G.; Janssen-Claessen, T.
Purification of coagulation factors and preparation of reagents for chromogenic substrate assays
Methods Enzym. Anal. , 3rd Ed. (Bergmeyer, H. U. , ed. )
5
390-394
1986
Bos taurus
-
brenda
Osterud, B.; Bouma, B.N.; Griffin, J.H.
Human blood coagulation factor IX
J. Biol. Chem.
253
5946-5951
1978
Homo sapiens
brenda
Sturzebecher, J.; Kopetzki, E.; Bode, W.; Hopfner, K.P.
Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols
FEBS Lett.
412
295-300
1997
Homo sapiens
brenda
Morita, T.; Fukudome, K.; Miyata, T.; Iwanaga, S.
gamma-Carboxylglutamic acid (Gla)-domainless blood coagulation factor IXa species: preparation and properties
J. Biochem.
110
990-996
1991
Bos taurus
brenda
London, F.S.; Walsh, P.N.
Zymogen factor IX potentiates factor IXa-catalyzed activation
Biochemistry
39
9850-9858
2000
Homo sapiens
brenda
Hopfner, K.P.; Lang, A.; Karcher, A.; Sichler, K.; Kopetzki, E.; Barndstetter, H.; Huber, R.; Bode, W.; Engh, R.A.
Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding
Structure Fold. Des.
7
989-996
1999
Homo sapiens
brenda
Fay, P.J.; Koshibu, K.; Mastri, M.
The A1 and the A2 subunits of factor VIIIa synergistically stimulate factor IXa catalytic activity
J. Biol. Chem.
274
15401-15406
1999
Homo sapiens
brenda
Ahmed, S.S.; Rawala-Sheikh, R.; Monroe, D.M.; Roberts, H.R.; Walsh, P.N.
Comparative platelet binding and kinetic studies with normal and variant factor IXa molecules
J. Biol. Chem.
265
20907-20911
1990
Homo sapiens
brenda
Blostein, M.D.; Rigby, A.C.; Furie, B.C.; Furie, B.; Gilbert, G.E.
Amphipathic helices support function of blood coagulation factor IXa
Biochemistry
39
12000-12006
2000
Homo sapiens
brenda
Falls, L.A.; Furie, B.; Furie, B.C.
Role of phosphatidylethanolamine in assembly and function of the factor IXa-factor VIIIa complex on membrane surfaces
Biochemistry
39
13216-13222
2000
Homo sapiens
brenda
Ahmad, S.S.; Walsh, P.N.
Coordinate binding studies of the substrate (factor X) with the cofactor (factor VIII) in the assembly of the factor X activating complex on the activated platelet surface
Biochemistry
41
11269-11276
2002
Homo sapiens
brenda
Bedsted, T.; Swanson, R.; Chuang, Y.J.; Bock, P.E.; Bjork, I.; Olson, S.T.
Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites
Biochemistry
42
8143-8152
2003
Homo sapiens
brenda
Bajaj, S.P.; Schmidt, A.E.; Mathur, A.; Padmanabhan, K.; Zhong, D.; Mastri, M.; Fay, P.J.
Factor IXa:factor VIIIa interaction. helix 330-338 of factor ixa interacts with residues 558-565 and spatially adjacent regions of the a2 subunit of factor VIIIa
J. Biol. Chem.
276
16302-16309
2001
Homo sapiens (P00740)
brenda
Wilkinson, F.H.; London, F.S.; Walsh, P.N.
Residues 88-109 of factor IXa are important for assembly of the factor X activating complex
J. Biol. Chem.
277
5725-5733
2002
Homo sapiens
brenda
Yang, L.; Manithody, C.; Olson, S.T.; Rezaie, A.R.
Contribution of basic residues of the autolysis loop to the substrate and inhibitor specificity of factor IXa
J. Biol. Chem.
278
25032-25038
2003
Homo sapiens (P00740)
brenda
Blostein, M.D.; Furie, B.C.; Rajotte, I.; Furie, B.
The Gla domain of factor IXa binds to factor VIIIa in the tenase complex
J. Biol. Chem.
278
31297-31302
2003
Homo sapiens
brenda
Wiebe, E.M.; Stafford, A.R.; Fredenburgh, J.C.; Weitz, J.I.
Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide
J. Biol. Chem.
278
35767-35774
2003
Homo sapiens
brenda
Rohlena, J.; Kolkman, J.A.; Boertjes, R.C.; Mertens, K.; Lenting, P.J.
Residues Phe342-Asn346 of activated coagulation factor IX contribute to the interaction with low density lipoprotein receptor-related protein
J. Biol. Chem.
278
9394-9401
2003
Homo sapiens
brenda
Rusconi, C.P.; Scardino, E.; Layzer, J.; Pitoc, G.A.; Ortel, T.L.; Monroe, D.; Sullenger, B.A.
RNA aptamers as reversible antagonists of coagulation factor IXa
Nature
419
90-94
2002
Homo sapiens
brenda
Panteleev, M.A.; Saenko, E.L.; Ananyeva, N.M.; Ataullakhanov, F.I.
Kinetics of Factor X activation by the membrane-bound complex of Factor IXa and Factor VIIIa
Biochem. J.
381
779-794
2004
Homo sapiens
brenda
Yang, X.; Walsh, P.N.
An ordered sequential mechanism for Factor IX and Factor IXa binding to platelet receptors in the assembly of the Factor X-activating complex
Biochem. J.
390
157-167
2005
Homo sapiens
brenda
Neuenschwander, P.F.
Exosite occupation by heparin enhances the reactivity of blood coagulation factor IXa
Biochemistry
43
2978-2986
2004
Homo sapiens
brenda
Batt, D.G.; Qiao, J.X.; Modi, D.P.; Houghton, G.C.; Pierson, D.A.; Rossi, K.A.; Luettgen, J.M.; Knabb, R.M.; Jadhav, P.K.; Wexler, R.R.
5-Amidinoindoles as dual inhibitors of coagulation factors IXa and Xa
Bioorg. Med. Chem. Lett.
14
5269-5273
2004
Homo sapiens
brenda
Qiao, J.X.; Cheng, X.; Modi, D.P.; Rossi, K.A.; Luettgen, J.M.; Knabb, R.M.; Jadhav, P.K.; Wexler, R.R.
5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa
Bioorg. Med. Chem. Lett.
15
29-35
2005
Homo sapiens
brenda
Lu, G.; Broze, G.J.; Krishnaswamy, S.
Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III
J. Biol. Chem.
279
17241-17249
2004
Homo sapiens
brenda
Butenas, S.; Orfeo, T.; Gissel, M.T.; Brummel, K.E.; Mann, K.G.
The significance of circulating factor IXa in blood
J. Biol. Chem.
279
22875-22882
2004
Homo sapiens
brenda
Yang, X.; Chang, Y.J.; Lin, S.W.; Walsh, P.N.
Identification of residues Asn89, Ile90, and Val107 of the factor IXa second epidermal growth factor domain that are essential for the assembly of the factor X-activating complex on activated platelets
J. Biol. Chem.
279
46400-46405
2004
Homo sapiens (P00740)
brenda
Schmidt, A.E.; Stewart, J.E.; Mathur, A.; Krishnaswamy, S.; Bajaj, S.P.
Na+ site in blood coagulation factor IXa: effect on catalysis and factor VIIIa binding
J. Mol. Biol.
350
78-91
2005
Homo sapiens (P00740)
brenda
Ndonwi, M.; Broze, G.; Bajaj, S.P.
The first epidermal growth factor-like domains of factor Xa and factor IXa are important for the activation of the factor VII-tissue factor complex
J. Thromb. Haemost.
3
112-118
2005
Homo sapiens
brenda
London, F.S.; Marcinkiewicz, M.; Walsh, P.N.
PAR-1-stimulated factor IXa binding to a small platelet subpopulation requires a pronounced and sustained increase of cytoplasmic calcium
Biochemistry
45
7289-7298
2006
Homo sapiens
brenda
Misenheimer, T.M.; Buyue, Y.; Sheehan, J.P.
The heparin-binding exosite is critical to allosteric activation of factor IXa in the intrinsic tenase complex: the role of arginine 165 and factor X
Biochemistry
46
7886-7895
2007
Homo sapiens
brenda
Neuenschwander, P.F.; Williamson, S.R.; Nalian, A.; Baker-Deadmond, K.J.
Heparin modulates the 99-loop of factor IXa: effects on reactivity with isolated Kunitz-type inhibitor domains
J. Biol. Chem.
281
23066-23074
2006
Homo sapiens (P00740)
brenda
Gale, A.J.; Radtke, K.P.; Cunningham, M.A.; Chamberlain, D.; Pellequer, J.L.; Griffin, J.H.
Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants
J. Thromb. Haemost.
4
1315-1322
2006
Homo sapiens
brenda
Scheiflinger, F.; Dockal, M.; Rosing, J.; Kerschbaumer, R.J.
Enhancement of the enzymatic activity of activated coagulation factor IX by anti-factor IX antibodies
J. Thromb. Haemost.
6
315-322
2008
Homo sapiens
brenda
Yang, L.; Gopalakrishna, K.; Manithody, C.; Rezaie, A.R.
Expression, purification and characterization of factor IX derivatives using a novel vector system
Protein Expr. Purif.
50
196-202
2006
Homo sapiens (P00740)
brenda
Gopalakrishna, K.; Rezaie, A.R.
The influence of sodium ion binding on factor IXa activity
Thromb. Haemost.
95
936-941
2006
Homo sapiens
brenda
Zoegg, T.; Brandstetter, H.
Activation mechanisms of coagulation factor IX
Biol. Chem.
390
391-400
2009
Homo sapiens
brenda
Yang, Y.H.; Chien, D.; Wu, M.; FitzGerald, J.; Grossman, J.M.; Hahn, B.H.; Hwang, K.K.; Chen, P.P.
Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin
J. Immunol.
182
1674-1680
2009
Homo sapiens
brenda
Becker, R.C.; Oney, S.; Becker, K.C.; Sullenger, B.
Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor
Ann. N. Y. Acad. Sci.
1175
61-70
2009
Homo sapiens
brenda
Gettins, P.G.; Olson, S.T.
Activation of antithrombin as a factor IXa and Xa inhibitor involves mitigation of repression rather than positive enhancement
FEBS Lett.
583
3397-3400
2009
Homo sapiens
brenda
Kim, W.H.; Kim, J.S.; Kim, J.S.; Yoon, Y.; Lee, G.M.
Effect of Ca2+ and Mg2+ concentration in culture medium on the activation of recombinant factor IX produced in Chinese hamster ovary cells
J. Biotechnol.
142
275-278
2009
Homo sapiens
brenda
Hartmann, R.; Dockal, M.; Kammlander, W.; Panholzer, E.; Nicolaes, G.A.; Fiedler, C.; Rosing, J.; Scheiflinger, F.
Factor IX mutants with enhanced catalytic activity
J. Thromb. Haemost.
7
1656-1662
2009
Homo sapiens
brenda
Zgg, T.; Brandstetter, H.
Structural basis of the cofactor- and substrate-assisted activation of human coagulation factor IXa
Structure
17
1669-1678
2009
Homo sapiens (P00740), Homo sapiens
brenda
Hosseini, S.; Zomorodipour, A.; Jalal, R.; Sabouni, F.; Ataei, F.
A study of the expression of functional human coagulation factor IX in keratinocytes using a nonviral vector regulated by K14 promoter
Appl. Biochem. Biotechnol.
162
1599-1611
2010
Homo sapiens
brenda
Misenheimer, T.M.; Sheehan, J.P.
The regulation of factor IXa by supersulfated low molecular weight heparin
Biochemistry
49
9997-10005
2010
Homo sapiens
brenda
Yang, L.; Manithody, C.; Qureshi, S.H.; Rezaie, A.R.
Role of the residues of the 39-loop in determining the substrate and inhibitor specificity of factor IXa
J. Biol. Chem.
285
28488-28495
2010
Homo sapiens
brenda
Wang, S.; Beck, R.; Blench, T.; Burd, A.; Buxton, S.; Malic, M.; Ayele, T.; Shaikh, S.; Chahwala, S.; Chander, C.; Holland, R.; Merette, S.; Zhao, L.; Blackney, M.; Watts, A.
Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis
J. Med. Chem.
53
1465-1472
2010
Homo sapiens
brenda
Wang, S.; Beck, R.; Burd, A.; Blench, T.; Marlin, F.; Ayele, T.; Buxton, S.; Dagostin, C.; Malic, M.; Joshi, R.; Barry, J.; Sajad, M.; Cheung, C.; Shaikh, S.; Chahwala, S.; Chander, C.; Baumgartner, C.; Holthoff, H.P.; Murray, E.; Blackney, M.; Giddings, A.
Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors
J. Med. Chem.
53
1473-1482
2010
Homo sapiens
brenda
Chang, L.; Yang, C.; Chua, A.; Lin, Y.; Lai, S.
Sustained release of transgenic human factor IX: Preparation, characterization, and in vivo efficacy
Mol. Pharm.
8
1767-1774
2011
Homo sapiens
brenda
Johnson, D.J.; Langdown, J.; Huntington, J.A.
Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex
Proc. Natl. Acad. Sci. USA
107
645-650
2010
Homo sapiens (P00740)
brenda
Wu, H.; Xu, X.; Zhang, L.; Shen, D.; Peng, L.; Zhang, Y.; Song, J.
Mg(II)-induced binding of factor IX-binding protein from the venom of Agkistrodon Halys Pallas with factor Xa
Toxicon
55
1358-1364
2010
Homo sapiens
brenda
Cunha, N.; Murad, A.; Ramos, G.; Maranhao, A.; Brgido, M.; Araujo, A.; Lacorte, C.; Aragao, F.; Covas, D.; Fontes, A.; Souza, G.; Vianna, G.; Rech, E.
Accumulation of functional recombinant human coagulation factor IX in transgenic soybean seeds
Transgenic Res.
20
841-855
2011
Homo sapiens (P00740), Homo sapiens
brenda
Venkateswarlu, D.
Structural insights into the interaction of blood coagulation co-factor VIIIa with factor IXa: a computational protein-protein docking and molecular dynamics refinement study
Biochem. Biophys. Res. Commun.
452
408-414
2014
Homo sapiens
brenda
Branchini, A.; Campioni, M.; Mazzucconi, M.; Biondo, F.; Mari, R.; Bicocchi, M.; Bernardi, F.; Pinotti, M.
Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity
FEBS Lett.
587
3249-3253
2013
Homo sapiens
brenda
Sullenger, B.; Woodruff, R.; Monroe, D.M.
Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction
J. Biol. Chem.
287
12779-12786
2012
Homo sapiens
brenda
Geng, Y.; Verhamme, I.M.; Messer, A.; Sun, M.F.; Smith, S.B.; Bajaj, S.P.; Gailani, D.
A sequential mechanism for exosite-mediated factor IX activation by factor XIa
J. Biol. Chem.
287
38200-38209
2012
Homo sapiens
brenda
Yang, L.; Rezaie, A.R.
Residues of the 39-loop restrict the plasma inhibitor specificity of factor IXa
J. Biol. Chem.
288
12692-12698
2013
Bos taurus, Mus musculus
brenda
Bloem, E.; Meems, H.; van den Biggelaar, M.; Mertens, K.; Meijer, A.B.
A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX
J. Biol. Chem.
288
26105-26111
2013
Homo sapiens
brenda
Wakabayashi, H.; Fay, P.J.
Replacing the factor VIII C1 domain with a second C2 domain reduces factor VIII stability and affinity for factor IXa
J. Biol. Chem.
288
31289-31297
2013
Homo sapiens
brenda
Neuenschwander, P.F.; Deadmond, K.J.; Zepeda, K.; Rutland, J.
Correlation of factor IXa subsite modulations with effects on substrate discrimination
J. Thromb. Haemost.
10
382-389
2012
Homo sapiens
brenda
Majumder, R.; Koklic, T.; Sengupta, T.; Cole, D.; Chattopadhyay, R.; Biswas, S.; Monroe, D.; Lentz, B.R.
Soluble phosphatidylserine binds to two sites on human factor IXa in a Ca2+ dependent fashion to specifically regulate structure and activity
PLoS ONE
9
e100006
2014
Homo sapiens
brenda
Kristensen, L.H.; Olsen, O.H.; Blouse, G.E.; Brandstetter, H.
Releasing the brakes in coagulation factor IXa by co-operative maturation of the substrate-binding site
Biochem. J.
473
2395-2411
2016
Homo sapiens (P00740)
brenda
Meng, D.; Andre, P.; Bateman, T.J.; Berger, R.; Chen, Y.H.; Desai, K.; Dewnani, S.; Ellsworth, K.; Feng, D.; Geissler, W.M.; Guo, L.; Hruza, A.; Jian, T.; Li, H.; Metzger, J.; Parker, D.L.; Reichert, P.; Sherer, E.C.; Smith, C.J.; Sonatore, L.M.; Tschirret-Guth, R.; Wu, J.; Xu, J.; Zhang, T.; Campeau, L.C.; Orr,
Development of a novel tricyclic class of potent and selective FIXa inhibitors
Bioorg. Med. Chem. Lett.
25
5437-5443
2015
Homo sapiens
brenda
Sakurada, I.; Endo, T.; Hikita, K.; Hirabayashi, T.; Hosaka, Y.; Kato, Y.; Maeda, Y.; Matsumoto, S.; Mizuno, T.; Nagasue, H.; Nishimura, T.; Shimada, S.; Shinozaki, M.; Taguchi, K.; Takeuchi, K.; Yokoyama, T.; Hruza, A.; Reichert, P.; Zhang, T.; Wood, H.B.; Nakao, K.; Furusako, S.
Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors
Bioorg. Med. Chem. Lett.
27
2622-2628
2017
Homo sapiens (P00740)
brenda
Kitazawa, T.; Shima, M.
Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity
Int. J. Hematol.
111
20-30
2018
Homo sapiens
brenda
Perot, E.; Enjolras, N.; Le Quellec, S.; Indalecio, A.; Girard, J.; Negrier, C.; Dargaud, Y.
Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity
Thromb. Res.
135
1017-1024
2015
Homo sapiens
brenda